PTC Therapeutics (PTCT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.92
- Estimate
- $0.34
- Surprise
- +170.6%
- Revenue (period 2026-06-30)
- $360.5M
- Score at report (before → after)
- 6.0 → 6.5/10
Revenue source: xbrl.
How the report landed
PTC Therapeutics (PTCT) beat the $0.34 estimate with diluted EPS of $0.92 — a large 170.6% upside surprise. TrendMatrix's engine moved from Sell (6.0/10) to Buy (Wait) at 6.5/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PTCT Sell at 6.2/10.
3 of the last 4 quarters beat the estimate; this quarter's +170.6% surprise compares with a +9.3% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Risk below floor (2.8 < 3.0)
- Value-trap signals (2/5): Revenue declining (-22.6% YoY), Negative free cash flow
- Momentum score 2.0/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $66.06
- Price target
- $86.38
- Stop
- $63.93
- Upside to target
- +30.8%
- Reward-to-risk
- 4.9:1
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
PTCT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $5.51B
- P/E (fwd)
- 26.4
- 52-week range
- $57.74–$90.87
- Off 52-week high
- 27.3%
- RSI (14)
- 38
- Volume vs avg
- 0.96×
- Score today
- 6.2/10